Business Context and Reporting Period
This Form 6-K filing by ProQR Therapeutics N.V. covers the month of December 2021. The report details the entry into a material definitive agreement on December 29, 2021, specifically a Third Amendment to the Company's Loan and Security Agreement. The Company is a foreign private issuer based in Leiden, The Netherlands.
Key Financial Metrics and Debt Structure
The filing focuses on debt financing rather than operational financial performance metrics such as revenue or profit, which are not provided in this document.
- Existing Debt: The Original Term Loan (first tranche) remains outstanding and unmodified regarding amounts, interest rate, maturity, and repayment schedule.
- New Financing Capacity: The Amended Loan Agreement provides for up to $90.0 million in additional term loans, structured in three tranches of $30.0 million each.
- Funding Status: The First Installment of $30.0 million was drawn down on December 30, 2021. The Second and Third Installments are contingent on achieving specified milestones within 9 and 18 months, respectively.
- Interest Rates: The First Installment bears an interest rate of 8.2% per annum. The Second and Third Installments bear an interest rate of 8.0% per annum.
- Fees: An unused line fee of 0.5% per annum applies to undrawn tranches, plus an additional 1.0% per annum fee payable retroactively upon milestone achievement.
- Repayment Terms: Maturity is 54 months after the Amendment Date. Amortized payments commence 33 months after the Amendment Date in eight equal quarterly payments.
- Equity Components: Lenders received warrants to purchase 376,952 Ordinary Shares at an exercise price of $11.94 per share. Loans are convertible into Ordinary Shares at a conversion price of $11.94 per share.
Material Changes Versus Prior Period
The primary material change is the restructuring of the undrawn tranches of the Original Loan Agreement. The two undrawn tranches were replaced by the new Installment Loans structure. The Original Term Loan remains unchanged. The Company has incurred new debt obligations and issued new equity-linked instruments (warrants) not present in the prior period.
Guidance, Risks, and Contingencies
Contingencies and Milestones: Access to the remaining $60.0 million of the new facility is strictly contingent upon the Company achieving specified milestones within defined timeframes (9 months for the Second Installment, 18 months for the Third Installment).
Risks and Covenants: The Amended Loan Agreement includes affirmative and negative covenants, including minimum cash requirements. Failure to comply could result in the immediate acceleration of all obligations. The agreement also restricts the ability to incur additional indebtedness, engage in mergers, or sell assets without lender consent.
Prepayment and Conversion: Borrowers may prepay loans after 12 months (Installment Loans) or 6 months (Original Term Loan) subject to a 1.0% prepayment fee. Lenders have the right to convert outstanding amounts into Ordinary Shares during the notice period for prepayment.
Important Facts for Investor Verification
- Verify the specific clinical or operational milestones required to trigger the $30.0 million Second and Third Installments.
- Confirm the current cash position to ensure compliance with the minimum cash covenants required by the Amended Loan Agreement.
- Assess the potential dilution impact of the 376,952 warrants issued and the potential conversion of up to $90.0 million of debt at $11.94 per share.
- Review the total outstanding principal balance of the Original Term Loan to understand the full debt load alongside the new $30.0 million drawdown.
- Monitor the Company's ability to meet the 33-month deferral period before amortized payments begin on the new loans.